Sickle cell disease is the most common inherited blood disorder in America.
Clinical trial findings showed both treatments could reduce pain from vaso-occlusive events, hallmarks of sickle cell disease.
A cutting-edge cure or CRISPR catastrophe? That’s the question facing regulators.